Homologous recombination

Homologous recombination (HR) is the high-fidelity pathway for repairing DNA double-strand breaks (DSBs) and stalled replication forks. Unlike the error-prone non-homologous-end-joining (NHEJ) pathway, HR uses an intact homologous DNA template — typically the sister chromatid — to restore sequence information precisely. This template dependency restricts HR to the S and G2 phases of the cell cycle, when sister chromatids are available. HR fidelity declines with age through multiple mechanisms — reduced expression of HR effectors (brca1 expression is lower in aged tissues), accumulating DSBs that compete for limited repair capacity, and age-associated shifts in the balance between HR and error-prone NHEJ. Inherited mutations in HR genes (brca1, brca2, atm, FANC genes) cause progeroid syndromes and dramatically elevated cancer risk. The clinical exploitation of HR deficiency — PARP inhibitor synthetic lethality — represents one of the most successful precision-oncology strategies of the past two decades.

Mechanism: five steps from break to restoration

Step 1 — DSB recognition and signaling (MRN complex)

DSBs are sensed within seconds by the MRN complex (MRE11–RAD50–NBS1). MRE11 provides nuclease activity; RAD50 bridges DNA ends via its coiled-coil arms; NBS1 (nibrin, encoded by NBN) mediates nuclear localization and recruits atm kinase. ATM activation triggers H2AX phosphorylation (γH2AX) to mark the DSB and amplify the damage signal across megabase chromatin domains ¹.

The MRN complex also initiates 5′ end resection — the creation of 3′ single-stranded DNA (ssDNA) tails that are essential for strand invasion downstream. Short-range resection is executed by the MRE11 nuclease; long-range resection requires CtIP (RBBP8) in cooperation with EXO1 or the BLM–DNA2 complex ¹.

Step 2 — ssDNA coating by RPA

The 3′ ssDNA tails generated by resection are rapidly coated by the heterotrimer RPA (RPA1–RPA2–RPA3), which stabilizes the single-stranded intermediate and prevents secondary-structure formation. RPA-coated ssDNA recruits ATR–ATRIP to activate the S/G2 checkpoint while repair proceeds.

Step 3 — RAD51 nucleofilament assembly (the BRCA1–PALB2–BRCA2 mediator axis)

The central enzymatic step of HR is the formation of a RAD51 nucleofilament on the RPA-coated ssDNA tail — the species that catalyzes homology search and strand exchange. RAD51 cannot displace RPA from ssDNA without mediator proteins.

The essential mediator axis operates as follows:

BRCA1 (in complex with BARD1) is recruited to DSB-flanking chromatin via ubiquitylated H2A and interaction with CtIP. BRCA1 directly interacts with PALB2 ¹.
PALB2 (partner and localizer of BRCA2) bridges BRCA1 and BRCA2 in chromatin; without PALB2, BRCA2 cannot be recruited to damage sites.
BRCA2 loads RAD51 onto the RPA-coated ssDNA, replacing RPA and forming the active nucleofilament ².

BRCA1 is required for HR: mouse ES cells harboring Brca1 mutations show a 5- to 6-fold reduction in homology-directed repair of I-SceI–induced DSBs relative to wild-type controls, while no gross defect in NHEJ is observed — NHEJ events are modestly elevated 1.5- to 1.6-fold in Brca1-null cells, consistent with partial compensatory rerouting ². BRCA2 is independently required: Brca2-deficient cells show a similar severe HR defect — RAD51 focus formation after irradiation is abrogated, and DSBs are instead channeled into mutagenic repair ³.

Step 4 — Strand invasion, D-loop extension, and DNA synthesis

The RAD51 nucleofilament performs homology search in three-dimensional nuclear space and catalyzes ATP-dependent strand invasion into the intact duplex sister chromatid. The displaced strand forms a D-loop. DNA polymerase δ extends the 3′ invading end using the sister chromatid as template ¹.

Step 5 — Holliday junction resolution

The D-loop intermediate is resolved via one of several routes:

DSBR (double-strand break repair): second-end capture forms a double Holliday junction (dHJ); resolution by structure-specific endonucleases (MUS81–EME1, SLX1–SLX4, GEN1) — can produce crossovers.
SDSA (synthesis-dependent strand annealing): the extended invading strand is displaced and anneals to the resected second end — non-crossover only. Predominant in mitotic cells.
SSA (single-strand annealing): annealing of resected ends at flanking repeat sequences; intrinsically deletion-generating and RAD51-independent.

Cell-cycle restriction: why HR is S/G2-specific

HR is suppressed in G1 by multiple mechanisms:

53BP1 and RIF1 promote NHEJ in G1 by blocking CtIP-mediated resection. 53BP1 occupies DSB-flanking chromatin and prevents end processing; its activity is antagonized in S/G2 by BRCA1 ⁴. This makes the BRCA1–53BP1 balance a key regulator of repair-pathway choice.
CDK-dependent phosphorylation of CtIP (on Thr847/Ser327) is required for its resection activity and peaks in S/G2.
Cyclin B1–CDK1 phosphorylates BRCA2 to release it from nuclear retention signals, enabling loading to damage sites in G2.

The practical consequence: DSBs that arise in post-mitotic or G0/G1 cells cannot use HR. With age, cells accumulate DSBs but an increasing fraction are in G1 or post-mitotic states — biasing repair toward error-prone NHEJ and NHEJ-independent alternative end-joining.

Negative regulation by nuclear cGAS

A second layer of HR regulation — distinct from the CDK/53BP1 cell-cycle axis — operates through the chromatin-bound pool of cGAS (cyclic GMP–AMP synthase). cGAS was originally characterized as a cytosolic DNA sensor that activates innate immunity, but a nuclear subpopulation physically suppresses HR at DSB sites in human and mouse cells ⁵.

Liu et al. 2018 — nuclear cGAS suppresses HR and promotes tumorigenesis

Liu et al. established that nuclear cGAS impairs the assembly of HR repair complexes — limiting RAD51 loading, BRCA1 recruitment, and MRN function at DSB sites — thereby reducing HR fidelity and promoting genome instability and tumorigenesis ⁵. The nuclear suppressive effect is normally transient: cGAS is evicted from chromatin via a two-step mechanism involving TRIM41-mediated ubiquitination (signaling for removal) followed by extraction by the segregase P97 (VCP/CDC48). Under normal conditions this eviction is sufficient to restore partial HR access, but the baseline suppression effect is non-trivial — nuclear cGAS constitutes a standing brake on HR capacity in human and mouse cells ⁵. This paper is closed-access and is not available in a local paper archive. Quantitative specifics (fold-reduction in HR, n per group, p-values) cannot be confirmed from the abstract alone. no-fulltext-access

Chen et al. 2025 — NMR cGAS resists eviction, potentiating HR via FANCI–RAD50

Chen et al. defined the proximal molecular mechanism connecting nuclear cGAS retention to active HR stimulation ⁶. Naked mole-rat (NMR) cGAS carries four amino acid substitutions relative to human and mouse cGAS that: (1) weaken TRIM41-mediated ubiquitination of cGAS, and (2) reduce cGAS interaction with the P97 segregase. Both changes oppose chromatin eviction, resulting in prolonged NMR cGAS retention at damage sites. Rather than being inert when retained, NMR cGAS acts as a scaffold that enhances the interaction between FANCI and RAD50 at DSBs — directly promoting RAD50 recruitment and MRN complex amplification at the break, and thereby potentiating HR repair. The four-AA residues are reported to mediate cGAS’s role in antagonizing cellular and tissue aging, and their presence is associated with lifespan extension in the experimental system ⁶. This paper is also closed-access; quantitative details are unavailable. no-fulltext-access

Note on FANCI: FANCI was previously associated in this wiki primarily with ICL repair in the Fanconi anemia pathway. Chen et al. 2025 reveals a broader DSB-repair role — FANCI participates in RAD50 recruitment during HR via cGAS scaffolding — extending its relevance beyond the FANC pathway canonical context.

Therapeutic implications

The cGAS-HR-brake axis opens a hypothetical new lever for HR enhancement in aged tissues:

TRIM41 inhibition — blocking the E3 ubiquitin ligase that tags cGAS for eviction would prolong human cGAS chromatin retention, mimicking the NMR phenotype. No TRIM41 inhibitor exists with established specificity; on-target toxicity risk is unclear. needs-replication
P97/VCP inhibitor — P97 segregase inhibitors (e.g., NMS-873, CB-5083) are in early oncology development; applying them to extend cGAS chromatin retention in aged non-dividing cells is a hypothesis only ⁵. needs-human-replication long-term-unknown
NMR four-AA cGAS variant gene therapy — introducing the NMR residues into human cGAS by gene editing (CRISPR base editing of the endogenous locus, or AAV delivery of the variant) is a longer-horizon concept proposed by the Chen 2025 authors ⁶. Safety concern: prolonged chromatin retention of cGAS could reduce the cytosolic pool available for antiviral immune sensing. no-mechanism

See chen-2025-nmr-cgas-hr-repair for the full mechanism summary and knowledge gaps.

Aging relevance

Decline in HR capacity with age

HR efficiency declines with organismal age through at least three mechanisms:

Reduced HR factor expression. brca1 mRNA and protein levels decline with age in multiple tissues, including breast epithelium, hematopoietic cells, and brain ⁷. The upstream driver is not fully established; age-associated epigenetic silencing (promoter hypermethylation, histone deacetylation) at the BRCA1 locus is a candidate no-mechanism. This shifts the BRCA1:53BP1 ratio toward NHEJ dominance.
Accumulating DSB burden. Mitochondrial ROS generation increases with age, oxidizing guanine and furanyl ring structures that convert to DSBs at replication forks. Higher DSB load in aged cells dilutes finite HR capacity per break ⁷.
Nuclear cGAS as a standing HR brake. Human and mouse cGAS exerts baseline suppressive pressure on HR via chromatin retention at DSBs (see “Negative regulation by nuclear cGAS” above) ⁵. Whether the efficiency of the TRIM41/P97 eviction mechanism changes with age — potentially altering the magnitude of cGAS-mediated HR suppression in aged cells — is not established. no-mechanism needs-replication

Dimension	Status
HR pathway conserved in humans?	yes
Age-associated HR decline in humans?	yes — epidemiological and molecular data
Replicated in humans (mechanistic)?	partial — BRCA1 expression data from human tissues; causal direction not fully established

HR-deficiency syndromes and aging

Mutations in HR pathway genes cause progeroid and cancer-predisposition phenotypes:

Gene	Syndrome	Phenotype
BRCA1	Hereditary breast/ovarian cancer	Accelerated genome instability; ~70% lifetime breast cancer risk
BRCA2	Hereditary breast/ovarian cancer; Fanconi anemia (biallelic)	As above; FA: bone marrow failure, developmental defects
ATM	Ataxia-telangiectasia	Neurodegeneration, immunodeficiency, premature aging, cancer
NBS1 (NBN)	Nijmegen breakage syndrome	Microcephaly, immunodeficiency, cancer predisposition
BLM	Bloom syndrome	Short stature, photosensitivity, high cancer risk, premature aging

These syndromes illustrate that intact HR is required for organismal healthspan, not just cancer avoidance. Loss of a single allele of Brca1 accelerates aging phenotypes in mice (mammary gland involution, hematopoietic dysfunction) — a progeroid trajectory that is partially rescued by concurrent p16 deletion ⁷. needs-human-replication

Connection to genomic instability hallmark

HR is a primary defense against the genomic-instability hallmark. DSBs repaired inaccurately by NHEJ or alternative end-joining are the most mutagenic lesions in the genome — they produce insertions, deletions, translocations, and loss-of-heterozygosity events. The accumulation of such mutations in stem cell compartments is a leading mechanistic proposal for age-related tissue dysfunction and oncogenic transformation (see dna-damage-response and genomic-instability).

Therapeutic landscape

PARP inhibitor synthetic lethality

The most clinically exploited feature of HR biology is synthetic lethality with PARP inhibition in HR-deficient tumors. The logic:

PARP1/2 repair single-strand breaks (SSBs) via base-excision repair. When PARP1 is inhibited, SSBs are not repaired and convert to DSBs at stalled replication forks.
In HR-proficient cells, these DSBs are repaired accurately.
In HR-deficient cells (BRCA1- or BRCA2-mutant), DSBs accumulate, leading to mitotic catastrophe and selective tumor-cell killing.

Two simultaneous 2005 Nature papers established the genetic proof of concept. Bryant et al. showed that PARP inhibitors (NU1025, AG14361) selectively killed BRCA2-deficient V-C8 cells and suppressed BRCA2-deficient xenograft tumor growth, with no toxicity to BRCA2-proficient controls ⁸. Farmer et al. independently demonstrated that BRCA1- or BRCA2-deficient mouse ES cells were hypersensitive to the potent PARP inhibitors KU0058684 and KU0058948, with SF50 sensitivity factors of 57-fold for BRCA1-deficient and 133-fold for BRCA2-deficient ES cells relative to wild-type, and greater than 1,000-fold enhanced sensitivity in BRCA2-deficient Chinese hamster ovary cells ⁹.

Clinical translation followed rapidly. Olaparib (first-in-class PARP inhibitor) showed antitumor activity in patients with BRCA-mutated solid tumors in a phase I trial — 12 of 19 evaluable BRCA-mutation carriers with ovarian, breast, or prostate cancer had clinical benefit (defined as radiologic or tumor-marker response, or stable disease for ≥4 months); 9 of the 19 had an objective radiologic response by RECIST ¹⁰. Olaparib was subsequently FDA-approved for BRCA-mutated ovarian (2014), breast (2018), pancreatic (2019), and prostate cancer (2020).

PARP inhibitor	Brand name	FDA approvals (as of 2025)
Olaparib	Lynparza	Ovarian, breast, pancreatic, prostate (BRCA-mutated or HRD)
Rucaparib	Rubraca	Ovarian (BRCA-mutated or HRD); withdrawn 2023 in some indications
Niraparib	Zejula	Ovarian (maintenance, irrespective of BRCA status)
Talazoparib	Talzenna	Breast (BRCA-mutated, HER2-negative)

PARP inhibitors are classified druggability-tier: 1 for this pathway — clinical drugs exist targeting the HR deficiency state.

HR as a target in aging (non-oncology)

Direct HR enhancement as a geroprotective strategy is an emerging but early area:

Small molecules that stimulate RAD51 loading (e.g., RS-1, a RAD51 activator) have been reported to promote HR in cell lines, but no aging-focused in vivo data exist needs-human-replication needs-replication.
Gene-therapy approaches to restore BRCA1 expression in aged tissues are hypothesized but not yet tested in vivo unsourced.
Relieving the cGAS-mediated HR brake — via TRIM41 inhibition, VCP inhibition, or introducing the NMR four-AA cGAS variant — is a newly proposed lever supported by Liu et al. 2018 and Chen et al. 2025 ⁵⁶. This is mechanistically the most defined of the HR-enhancement concepts but remains preclinical and theoretical for aging applications. See “Negative regulation by nuclear cGAS” above for full discussion.

Limitations and gaps

#gap/needs-replication — Quantitative estimates of age-associated HR decline (e.g., fold-reduction in HR frequency in aged vs young primary human cells) vary by tissue and assay; a systematic multi-tissue study in humans is lacking.
#gap/no-mechanism — The upstream regulator(s) responsible for BRCA1 transcript decline in aged tissues are not established.
#gap/long-term-unknown — The consequences of partial HR restoration (e.g., via RAD51 activators) on organismal aging vs oncogenesis risk have not been tested in vivo.
#gap/needs-canonical-id — WikiPathways ID for homologous recombination not confirmed; left null.
#gap/contradictory-evidence — The relative contribution of HR decline vs NHEJ mis-repair vs chromatin compaction to age-associated genomic instability is not resolved. Different model systems give different rank-orderings.

Footnotes

doi:10.1146/annurev.biochem.77.061306.125255 · San Filippo J, Sung P, Klein H · Annual Review of Biochemistry 2008 · review · model: eukaryotes (yeast + vertebrate systems) · comprehensive mechanistic review of HR: resection, RPA loading, Rad51 nucleofilament assembly, strand invasion, branch migration, resolution · cited_by: 1646 · archive: not_oa (no local PDF) ↩ ↩² ↩³ ↩⁴
doi:10.1016/s1097-2765(00)80202-6 · Moynahan ME, Chiu JW, Koller BH, Jasin M · Molecular Cell 1999 · in-vitro · n=multiple ES-cell clones (Brca1−/− line 236.44 vs Brca1+/− controls) · model: mouse ES cells (Brca1 hypomorphic null via hprt disruption) · HR frequency assayed by I-SceI endonuclease reporter at pim1 and Rb loci — 5- to 6-fold HR reduction in Brca1-null vs wild-type; NHEJ modestly elevated 1.5- to 1.6-fold (no gross NHEJ defect) · archive: locally downloaded ↩ ↩²
doi:10.1016/s1097-2765(01)00174-5 · Moynahan ME, Pierce AJ, Jasin M · Molecular Cell 2001 · in-vitro · n=multiple cell clones · model: mouse ES cells and human cancer cell lines with BRCA2 deletion · RAD51 focus formation abrogated after IR; HR severely impaired; NHEJ increases compensatorily · cited_by: 997 · archive: pending download ↩
doi:10.1016/j.molcel.2019.09.024 · Callen E et al. · Molecular Cell 2020 · in-vivo + in-vitro · model: mouse B cells + human cell lines · 53BP1 enforces pre-resection block (protecting DNA ends from MRN/CtIP) and post-resection block (preventing Rad52 annealing) — BRCA1 antagonizes both blocks to enable HR · cited_by: 126 · archive: pending download ↩
liu-2018-nuclear-cgas-hr-suppression · n=NR · in-vitro+in-vivo · doi:10.1038/s41586-018-0629-6 · PMID:30356214 · Liu H et al. · Nature · 2018 · model: human cell lines + mouse xenograft · “Nuclear cGAS suppresses DNA repair and promotes tumorigenesis” · established that nuclear cGAS inhibits HR (limiting RAD51/BRCA1/MRN function at DSB sites) and promotes tumorigenesis; eviction mechanism: TRIM41 ubiquitination + P97 segregase extraction · archive: not_oa (closed-access; no-fulltext-access) ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶
chen-2025-nmr-cgas-hr-repair · Science · 2025 · doi:10.1126/science.adp5056 · PMID:41066557 · in-vitro + in-vivo · model: multiple (cell lines + mouse + naked mole-rat) · “A cGAS-mediated mechanism in naked mole-rats potentiates DNA repair and delays aging” · four amino acid substitutions in NMR cGAS weaken TRIM41 ubiquitination and P97 interaction → prolonged chromatin retention → enhanced FANCI–RAD50 interaction → potentiated HR repair; four-AA variant mediates anti-aging function and lifespan extension in experimental system · #gap/no-fulltext-access ↩ ↩² ↩³ ↩⁴
doi:10.1016/j.molcel.2016.08.004 · White RR, Vijg J · Molecular Cell 2016 · review · model: multiple organisms + human epidemiology · synthesizes evidence that DSB accumulation and declining HR fidelity drive aging; BRCA1 expression decline with age in multiple tissues highlighted · cited_by: 237 · archive: pending download (bronze OA) ↩ ↩² ↩³
doi:10.1038/nature03443 · Bryant HE et al. · Nature 2005 · in-vitro + in-vivo · n=multiple cell lines; xenograft (40 CD-1 nude mice: 10 out of 20 V-C8 and 9 out of 20 V-C8+B2 xenograft take rate) · model: BRCA2-deficient V-C8 hamster cells; BRCA2-depleted MCF7/MDA-MB-231 human breast cancer cells; mouse xenograft · PARP inhibitors (NU1025, AG14361) selectively kill BRCA2-deficient cells; 3 of 5 V-C8 xenografts responded to AG14361 (including 1 complete remission); no toxicity to BRCA2-proficient controls · cited_by: 5038 · archive: locally downloaded ↩
doi:10.1038/nature03445 · Farmer H et al. · Nature 2005 · in-vitro + in-vivo · n=multiple cell lines; xenograft (BRCA2-deficient ES-cell teratocarcinoma in 40 athymic BALB/c-nude mice) · model: BRCA1- and BRCA2-deficient mouse ES cells; BRCA1-depleted MCF7 human breast cancer cells; BRCA2-deficient Chinese hamster ovary cells · KU0058684 (PARP1 IC50=3.2 nM) and KU0058948 (PARP1 IC50=3.4 nM): SF50 sensitivity 57-fold enhanced in BRCA1-deficient ES cells and 133-fold in BRCA2-deficient ES cells vs wild-type; >1,000-fold enhanced sensitivity in BRCA2-deficient CHO cells; PARP inhibition selectively blocked BRCA2-deficient xenograft tumor formation (P=0.03 vs vehicle; P=0.01 vs wild-type+KU0058684) · cited_by: 6496 · archive: locally downloaded ↩
doi:10.1056/NEJMoa0900212 · Fong PC et al. · NEJM 2009 · phase-I clinical trial · n=60 enrolled (22 confirmed BRCA1/2 mutation carriers + 1 strong family history); 19 evaluable BRCA-mutation carriers with ovarian, breast, or prostate cancer · model: humans with BRCA1/2-mutant solid tumors · olaparib: 12/19 (63%) BRCA-carrier evaluable patients had clinical benefit (radiologic or tumor-marker response OR stable disease ≥4 months); 9/19 had objective radiologic response by RECIST; maximum tolerated dose 400 mg BID; maximum administered dose 600 mg BID (dose-limiting toxicities: grade 3 mood alteration/fatigue, grade 4 thrombocytopenia, grade 3 somnolence) · cited_by: 3582 · archive: locally downloaded ↩

🧬 Aging Wiki

Explorer

homologous-recombination